Raymond James Financial Services Advisors Inc. grew its stake in shares of Novavax, Inc. (NASDAQ:NVAX – Get Rating) by 23.4% during the third quarter, Holdings Channel reports. The institutional investor owned 55,588 shares of the biopharmaceutical company’s stock after buying an additional 10,542 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Novavax were worth $1,012,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also recently made changes to their positions in NVAX. State Street Corp lifted its position in shares of Novavax by 31.4% during the 1st quarter. State Street Corp now owns 2,495,542 shares of the biopharmaceutical company’s stock valued at $183,797,000 after buying an additional 596,322 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Novavax by 139.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 488,744 shares of the biopharmaceutical company’s stock valued at $35,996,000 after buying an additional 284,344 shares in the last quarter. Credit Suisse AG lifted its position in shares of Novavax by 127.9% during the 2nd quarter. Credit Suisse AG now owns 331,823 shares of the biopharmaceutical company’s stock valued at $17,065,000 after buying an additional 186,228 shares in the last quarter. Candriam S.C.A. lifted its position in shares of Novavax by 2,203.1% during the 2nd quarter. Candriam S.C.A. now owns 134,894 shares of the biopharmaceutical company’s stock valued at $6,937,000 after buying an additional 129,037 shares in the last quarter. Finally, Centiva Capital LP lifted its holdings in Novavax by 1,201.1% in the 2nd quarter. Centiva Capital LP now owns 103,397 shares of the biopharmaceutical company’s stock worth $5,317,000 after purchasing an additional 112,787 shares in the last quarter. 45.70% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of research analysts recently commented on NVAX shares. B. Riley lowered their price target on Novavax from $74.00 to $37.00 and set a “buy” rating on the stock in a report on Monday, January 9th. Cowen lowered their price target on Novavax to $55.00 in a report on Thursday, October 13th. Jefferies Financial Group started coverage on Novavax in a report on Friday, December 2nd. They issued a “hold” rating on the stock. StockNews.com raised Novavax from a “sell” rating to a “hold” rating in a report on Saturday, November 19th. Finally, HC Wainwright lowered their price target on Novavax from $207.00 to $110.00 and set a “buy” rating on the stock in a report on Friday, December 30th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Novavax currently has a consensus rating of “Hold” and a consensus price target of $92.50.
Novavax Price Performance
Novavax (NASDAQ:NVAX – Get Rating) last issued its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported ($2.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.21 by ($4.36). The firm had revenue of $734.58 million during the quarter, compared to analyst estimates of $555.50 million. Novavax’s quarterly revenue was up 310.7% on a year-over-year basis. During the same quarter last year, the business earned ($4.31) earnings per share. On average, sell-side analysts expect that Novavax, Inc. will post -7.47 earnings per share for the current year.
Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
- Get a free copy of the StockNews.com research report on Novavax (NVAX)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.